Rhythm Reports Positive Phase 2 PWS Interim Data, But Competition and Funding Risks Loom

What happened

Rhythm Pharmaceuticals announced positive interim results from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS), showing BMI reductions and hunger improvements. While the data supports the company's platform narrative, it comes from a small open-label study, and management has previously cautioned that early-stage results may not predict Phase 3 outcomes. The PWS market is already contested by Soleno Therapeutics' VYKAT XR, which has an FDA-approved hyperphagia indication and established pricing, raising the bar for setmelanotide to differentiate. Rhythm continues to burn through cash with a net loss of ~$149M in the first nine months of 2025, relying on equity raises and a revenue-interest financing deal that limits financial flexibility. The stock already prices in successful label expansions, and with no margin of safety at ~$105, investors should weigh the incremental PWS data against the high execution risk and capital requirements.

Implication

While the Phase 2 PWS data adds scientific support for setmelanotide in a new indication, it does not materially de-risk the investment case given the intense competition from Soleno's VYKAT XR and the company's ongoing cash burn. Rhythm's valuation at ~$105 per share implies a high probability of successful outcomes across HO, PWS, and EMANATE, leaving little room for error if later-stage trials disappoint or commercial execution falters. The company's reliance on external capital and a revenue-interest financing structure creates downside risk; if the HO launch underperforms, further dilution or asset encumbrance could pressure shares. The interim data are from a small open-label study, and historical precedent in biotech suggests that early PWS results often fail to replicate in larger, controlled trials. Investors should monitor HO patient starts and payer coverage later this year as a more reliable indicator of franchise value, and wait for a better entry point near the attractive entry zone of $80.

Thesis delta

The incremental PWS data supports the broader MC4R platform story, but it does not change our WAIT rating given the stock's full valuation and the crowded PWS competitive landscape. Our attractive entry remains $80, and we need to see sustained HO sales growth and disciplined expense management to upgrade the thesis.